GBM
-
August 5, 2018
First Patient Dosed in Phase I/II Trial of Novel Immunotherapy Combination in Newly Diagnosed Glioblastoma Bookmark
Emma Shtivelman, PhDExcerpt from Targeted Oncology:
“The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma (GBM). Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.
“This study aims to investigate the efficacy of INO-5401, a T-cell activating immunotherapy agent encoding multiple antigens in GBM, and INO-9012, an immune activator encoding IL-12, in combination with the PD-1 inhibitor cemiplimab (REGN2810).”
Go to full article published by Targeted Oncology on July 9, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 10, 2017
Reengineering Immune System Cells to Treat Glioblastoma
Emma Shtivelman, PhDGlioblastoma multiforme (GBM) is a serious diagnosis. The search for better treatments is ongoing, but with little to show since the U.S. Food and Drug Administration (FDA) approved the use of the chemotherapy drug temozolomide with concurrent radiation 12 years ago, based on data showing modest improvement in patients’ survival. By now, a new cancer treatment approach known as CAR T-cell therapy is famous… Read more »
-
March 7, 2017
Clinical Trials Test Treatments for High-Grade Brain Tumors
Emma Shtivelman, PhDWith a few exceptions, glioblastoma (GBM) remains largely incurable, and the U.S. Food and Drug Administration (FDA) has approved few treatments for the disease. Surgery (when feasible), radiation, and temozolomide are used in most patients. But even if a newly diagnosed tumor can be surgically excised, recurrences are too common. In this blog post, I simply list some of the new treatments available in… Read more »